García-Villarreal, Ovidio A

ABSTRACT

The contemporary evolution of Transcatheter Aortic Valve Replacement (TAVR) into progressively younger populations represents one of the most consequential shifts in structural heart disease over the past decade. In their national analysis from the STS/ACC TVT Registry, Alabbadi et al. document not merely an epidemiologic trend, but a conceptual transformation in the management of patients younger than 65 years with aortic stenosis.
TAVR was originally reserved for individuals at prohibitive or extreme surgical risk. Following regulatory expansion by the U.S. Food and Drug Administration (FDA) in 2019,2 TAVR entered the low-risk arena, supported by pivotal randomized trials such as PARTNER 33 and Evolut Low Risk.4 These studies demonstrated non-inferiority, and in some cases, superiority,

  FULL TEXT PDF